Peptides Are Everywhere. Businesses Are Cashing In.
Summary
This episode examines the booming, unregulated market for experimental peptides, fueled by social media hype and celebrity endorsements. Reporter Sarah O'Brien details the health risks of self-injecting unapproved substances and the FDA’s shifting stance under Robert F. Kennedy Jr., who aims to loosen restrictions. Major telehealth companies are positioning themselves to capitalize on this potential regulatory change, sparking a debate over patient safety versus market access.
Topics discussed
Intro: The peptide craze and regulatory uncertainty
Show intro and sponsor advertisements
What are peptides and how the trend started
Risks, side effects, and the gray market
RFK Jr.'s influence on peptide regulation
Optum advertisement
FDA committee vote to lift compounding bans
Telehealth companies preparing for the market
Timeline for approval and public trust in wellness
Outro and credits
Listen ad-free on Castria